Author

B. Strobl

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:mouse· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:gene regulatory network inference· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

A. Aufinger· 1 shared B. Tichy· 1 shared C. Moreira Heliodoro· 1 shared C. Probst· 1 shared C. Sternberg· 1 shared D. Hromadova· 1 shared D. Lindner· 1 shared E. Read· 1 shared

Activity by Year

2021-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Aufinger

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

JUN mediates senescence and immune cell recruitment to prevent prostate cancer progression

T. Redmer, M. Raigel, C. Sternberg, R. Ziegler, C. Probst, D. Lindner, A. Aufinger, T. Limberger, K. Trachtova, P. Kodajova, S. Hoegler, M. Schlederer, S. Stoiber, M. Oberhuber, M. Bolis, , L. Kenner

This study shows JUN suppresses prostate cancer progression by inducing senescence and immune cell recruitment, with JUN depletion accelerating tumor growth.

bioRxiv · Nov 29, 2023 · PreprintCancer Biology

Sustained post-developmental T-bet expression is critical for the maintenance of type 1 innate lymphoid cells in vivo

J.-H. Schroeder, L. B. Roberts, K. Meissl, J. W. Lo, D. Hromadova, K. Hayes, T. Zabinski, E. Read, C. Moreira Heliodoro, R. Reis, J. K. Howard, R. K. Grencis, J. F. Neves, B. Strobl, G. M. Lord

This study shows that sustained T-bet expression is necessary for maintaining intestinal ILC1 in vivo, and ILC1 depletion protects against colitis, suggesting potential therapeutic targeting of T-bet for IBD treatment.

bioRxiv · Jun 5, 2021Immunology